Showing 193 results
- Statement /
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- Statement /
- Statement /
- Featured News /
Novartis announced the company’s financial results for the second quarter and first half of 2023.
- Statement /
- Pulse Update /
- Featured News /
Novartis announced the company’s financial results for the first quarter of 2023.
- Statement /
- Statement /
- Featured News /
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 20
- › Next page